The Neuropathy Daily
Everything New About Neuropathy Due to Benign and Malignant Disorders by Robert Z. Orlowski
Related Articles
Myeloma Paper of the Day, January 13th, suggested by Robert Orlowski – OncoDaily
Myeloma Paper of the Day, January 13th, suggested by Robert Orlowski / Andrew Spencer, Anna Kalff, Antonia Reale, Blood Cancer Journal, BRAF, cancer, Daniel
Conquer Cancer, the ASCO Foundation – Application deadline for Advanced Clinical Research Award is extended – OncoDaily
Conquer Cancer, the ASCO Foundation – Application deadline for Advanced Clinical Research Award is extended / Breast Cancer, cancer, Conquer Cancer,
Myeloma Paper of the Day, January 9th, suggested by Robert Orlowski – OncoDaily
Myeloma Paper of the Day, January 9th, suggested by Robert Orlowski / cancer, Maria-Victoria Mateos, MD Anderson Cancer Center, Myeloma Paper of the Day,
Myeloma Paper of the Day, January 2nd, suggested by Robert Orlowski – OncoDaily
Myeloma Paper of the Day, January 2nd, suggested by Robert Orlowski / Ana Gea, Ana Tobalina, Andrés Insunza, Aránzazu Bermúdez1, biopsy, cancer, Carmen
Myeloma Paper of the Day, December 27th, suggested by Robert Orlowski – OncoDaily
Myeloma Paper of the Day, December 27th, suggested by Robert Orlowski / Ahmad Basharat, Ahmed Hebishy, cancer, hematopoietic stem cell transplant, Iqra Anwar,
Myeloma Paper of the Day, December 21st, suggested by Robert Orlowski – OncoDaily
Myeloma Paper of the Day, December 21st, suggested by Robert Orlowski / Anne J. Novak, cancer, Hyo Jin Kim, Jonas Paludo, Jordan E. Krull, Jose…
Myeloma Paper of the Day, December 14th, suggested by Robert Orlowski – OncoDaily
Myeloma Paper of the Day, December 14th, suggested by Robert Orlowski / Andri Olafsson, Ásbjörn Jónsson, Bjarni Agnarsson, Brynjar Viðarsson, cancer, Edith
Paper: A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed By Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis
Program: Oral and Poster Abstracts Session: 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II Hematology Disease Topics & Pathways:…
Efficacy and safety of bendamustine, rituximab and bortezomib treatment in relapsed/refractory Waldenstrom Macroglobulinaemia: results of phase 2 single-arm FIL-BRB trial – PubMed
This multicentre phase II study Fondazione Italiana Linfomi (FIL)-bortezomib plus rituximab plus bendamustine (BRB) tested a combination of bendamustine (90 mg/m2 on days 1-2), rituximab…
Myeloma Paper of the Day, November 24th, suggested by Robert Orlowski – OncoDaily
Myeloma Paper of the Day, November 24th, suggested by Robert Orlowski / cancer, Chunyan Gu, Hui Shi, Jialei Mao, Jie Min, MD Anderson Cancer Center,…